You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

20 Results
Drug
Other Name(s): Vesanoid®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Drug
Other Name(s): Thalomid®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Drug
Other Name(s): Tykerb®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2022
Drug
Other Name(s): Mekinist®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2021
Drug
Other Name(s): Lenvima®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2023
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
  • trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trametinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2021
Regimen
Cancer Type:
Endocrine, 
Thyroid
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    lenvatinib - For the treatment of patients with locally recurrent or metastatic, progressive, radioactive-iodine-refractory differentiated thyroid cancer (DTC) according to criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lenvatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2020
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
ODB - General Benefit
    letrozole
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
palbociclib,
letrozole
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2021
Drug
Other Name(s): Lonsurf®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ribociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant according to clinical criteria
ODB - General Benefit
    letrozole
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
letrozole,
ribociclib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2021
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    lenvatinib - For the treatment of unresectable advanced hepatocellular carcinoma according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lenvatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2023
Regimen
Cancer Type:
Hematologic, 
Myelodysplastic Syndrome (MDS)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    luspatercept - For the treatment of red-blood cell (RBC) transfusion-dependent anemia associated with Myelodysplastic Syndromes (MDS), according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
luspatercept
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2023

Pages